ABI
ALKS icon

Adamant Biomedical Investments’s Alkermes ALKS Stock Holding History

Adamant Biomedical Investments’s Portfolio ALKS Stock Details ALKS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$2.63M Hold
45,000
– – 0.63% 54
2014
Q3 		$1.93M Buy
+45,000
New +$2.02M 0.48% 59

Other funds holding ALKS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adamant Biomedical Investments's ALKS Position: Q4 2014 in Review

Adamant Biomedical Investments held its Alkermes (ALKS) position steady in Q4 2014 at 45,000 shares worth $2.63M. The position accounts for 0.63% of the portfolio, ranked #54.

Adamant Biomedical Investments first reported a position in ALKS in Q3 2014 and has held it in 2 quarters since. 220 funds tracked by Wall St. Rank hold ALKS as of Q4 2014.

  • Adamant Biomedical Investments held 45,000 shares of Alkermes worth $2.63M as of Q4 2014.
  • Adamant Biomedical Investments left its Alkermes share count unchanged in Q4 2014.
  • Alkermes made up 0.63% of Adamant Biomedical Investments's portfolio in Q4 2014, its #54 holding.
  • Adamant Biomedical Investments first reported a position in Alkermes in Q3 2014 and has held it in 2 quarters since.
  • 220 funds tracked by Wall St. Rank held Alkermes as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.